For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen (AMGN) closed at $295.18 in the latest trading session, marking a -1.73% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Elsewhere, the Dow saw a ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

In a report released on July 8, Courtney Breen from Bernstein maintained a Buy rating on Amgen, with a price target of $350.00. The company’s shares closed yesterday at $295.27. Breen covers the ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

In the last year, many Amgen Inc. (NASDAQ:AMGN) insiders sold a substantial stake in the company which may have sparked ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...